Interfering with the PD-L1/PD-1 crosstalk enhanced anti-AML immunosurveillance in murine models and boosted the in vitro efficacy of CD33/CD3 bispecific antibodies (3, 85). This evidence concerns the gene PDCD1 and acute myeloid leukemia.